Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
about
alpha-Synuclein and neuronal cell deathDefinition of a molecular pathway mediating α-synuclein neurotoxicityM1 and M2 immune activation in Parkinson's Disease: Foe and ally?Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectorsComparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's DiseasePropagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseRole of microRNAs in the Regulation of α-Synuclein Expression: A Systematic ReviewParkinson's disease: animal models and dopaminergic cell vulnerabilityResistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activationTowards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in MacaqueExcess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1Value of genetic models in understanding the cause and mechanisms of Parkinson's diseaseAnimal models of Parkinson's disease: vertebrate geneticsParthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing miceDifferential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primatesASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegenerationProgressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation.Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson's disease.Large animal models are critical for rationally advancing regenerative therapiesSNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.Versatile somatic gene transfer for modeling neurodegenerative diseases.Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model tPET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.Lewy bodies.A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.Nonhuman primate models of Parkinson's disease.A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.Domain a' of protein disulfide isomerase plays key role in inhibiting alpha-synuclein fibril formation.Molecular insights into Parkinson's disease.Gene therapy progress and prospects: Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.AAV's Golden Jubilee.
P2860
Q21202835-008FCA06-B9DD-48BE-85FB-4D7CD1DD59DBQ26269832-D9911883-325E-41C4-B114-DEEA39BB5EA4Q27024667-85D4D7AB-27E8-4CBC-BDD6-8D96148D72E1Q27301058-8E206C72-9209-4426-92E1-CCEB08AD0C68Q27318127-724C0654-2DAB-4130-BA12-F06AB4E0BDA1Q27320553-2E80EB52-CA90-495E-915A-CC788912DF6FQ27322513-565DC303-46A8-4F3E-A95A-13A86AD19C29Q28068464-367C3187-5C39-4122-8AD2-068B954E94D9Q28080047-9C8E10B9-C77C-46F4-9CDB-D3286BB69D7EQ28080503-99DF6583-F04A-4AE5-A59D-C2D2B553A39EQ28477043-9CBB225B-77DA-437F-87DC-021499E7224CQ28554611-81B66C34-191C-4772-9F98-D2FED9ED8CCCQ28732131-0D33BBFE-330B-4258-A5B0-92168A8633EDQ30412016-8318D73A-3E70-4BC1-8917-A0FBFCF24EFCQ30429583-BA1B674E-EB4D-4956-8394-B1A4887FB763Q30547326-BE0F660B-EF0B-432F-BF24-769EBC34FBBBQ30856480-FB36D7CD-C32A-45F6-8C6B-C6B0D3E7D448Q33269934-9A52785D-DF64-461A-ADEC-6A89A48770C0Q33526342-661A6140-BEC6-449B-86B5-2F88C8A545EFQ33680232-6234FFF4-C3E3-42BB-8D6E-16F7E6BFFC77Q33731243-62ED27FA-049E-403D-85B1-D6152F3C3956Q33816233-0AD8BBC6-5DEC-4052-B9A8-F931081B24FFQ33847712-6FBDF7D9-1BFA-4537-8675-AE84C2FBA3D4Q33948478-19D6E441-A541-4461-AA0D-EB9566DD9D84Q33997655-8842D72D-6C12-4E2A-943A-A8622B9DD7E2Q33999256-545407F0-8966-4F46-B490-88C0694FA657Q34081400-6BFA2226-B2C8-42C4-A498-CC2ED91603A5Q34285870-B86AD3CB-35EB-4C7E-B07A-930B836886C6Q34321875-52343D56-E4ED-4ABD-BA11-662087CAAAA4Q34441377-AD7D845F-201F-4BAE-9459-256E35A4C4EAQ34465572-E28A7BA2-443F-434F-BA5D-36D2FFFB61C8Q34478663-5BF1FE43-0F59-4E49-AE80-664AF3C7F937Q34612993-19901FE9-3098-4F76-B5E9-58B5F2C8DAA7Q34665820-1E0B8DF0-7D08-4EA5-923C-5DF54B151FA5Q34795038-13BB0FCB-FB8A-44B1-92C5-CFC426E37D02Q34861594-2E421DD9-3BC1-49E6-9E99-E7BE4031161CQ34988753-11BAB1A8-25BE-419F-9FFA-3FB9207ADF73Q35206326-9D4FB0E3-92A3-4E44-AF1E-28DDC2936955Q35589979-8499C5FA-E2EB-4318-9238-D6A5E1D365D7Q35594880-9A36AAD7-B096-4C2A-A9EA-2A8A5D1F16B5
P2860
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Nigrostriatal alpha-synucleino ...... model of Parkinson's disease.
@ast
Nigrostriatal alpha-synucleino ...... model of Parkinson's disease.
@en
type
label
Nigrostriatal alpha-synucleino ...... model of Parkinson's disease.
@ast
Nigrostriatal alpha-synucleino ...... model of Parkinson's disease.
@en
prefLabel
Nigrostriatal alpha-synucleino ...... model of Parkinson's disease.
@ast
Nigrostriatal alpha-synucleino ...... model of Parkinson's disease.
@en
P2093
P2860
P921
P356
P1476
Nigrostriatal alpha-synucleino ...... model of Parkinson's disease.
@en
P2093
Deniz Kirik
Lucy E Annett
Nicholas Muzyczka
Ronald J Mandel
P2860
P304
P356
10.1073/PNAS.0536383100
P407
P577
2003-02-24T00:00:00Z